Abbott Laboratories (ABT)
NYSE: ABTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:02 PM ET · Delayed 15 min
ABT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $178.39B
- P/E (TTM)
- 38.43
- Forward P/E
- 17.35
- EPS (TTM)
- $2.68
- Dividend yield
- 2.45% ($2.52)
- Ex-dividend date
- Oct 15, 2026
- 52-week range
- 81.97 – 129.85
- Day range
- 102.80 – 105.50
- Volume / Avg
- 7.29M / 8.89M
- Beta
- —
- Shares outstanding
- 1.73B
52-week range
ABT stock today
Abbott Laboratories (ABT) closed at $103.00 on Nov 20, down 0.84% (-$0.87), versus the S&P 500's 3.70% decline. Shares are 20.7% below their 52-week high of $129.85, set on Dec 1, 2025 and 25.7% above the 52-week low of $81.97, in the middle of the past year's range. ABT is down 17.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 19.6%.
At 38.4x trailing earnings, Abbott Laboratories trades above the peer-group median of 21.7x. Its forward P/E of 17.3x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Abbott Laboratories pays an annual dividend of $2.52 per share, a 2.45% yield at the current price.
Summary generated from market data by MetaCap's automated system. Methodology
About Abbott Laboratories
Company profileAbbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Robert B. Ford
- Headquarters
- Abbott Park, IL
- Employees
- 122,000
- Website
- abbott.com
Financial highlights
Full financialsIn fiscal 2025, Abbott Laboratories generated $44.33 billion in revenue, up 5.7% from fiscal 2024, its 2nd consecutive year of revenue growth. Net income was $6.52 billion (-51.3% year over year), for a net margin of 14.7% versus a median of 15.9% in the prior 5 years. Gross margin was 56.4% (up from 55.4%) and operating margin 18.2%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $44.33B | $41.95B | $40.11B | $43.65B | $43.08B |
| Growth | +5.67% | +4.59% | -8.12% | +1.34% | +24.47% |
| Net income | $6.52B | $13.40B | $5.72B | $6.93B | $7.07B |
| EPS (diluted) | $3.72 | $7.64 | $3.26 | $3.91 | $3.94 |
Analyst forecast
ForecastConsensus (28 analysts)
buy
Avg. price target
$118.91+15.45%
- Strong buy 5
- Buy 18
- Hold 5
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 21, 2026
- EPS actual vs est.
- $1.42 vs $1.43
- Surprise
- -0.70%
Dividends
Dividend history- Annual dividend
- $2.52
- Dividend yield
- 2.45%
- Last payment
- $0.63
- Ex-dividend date
- Oct 15, 2026
ABT news
All ABT news- Abbott (ABT) Up 1.3% Since Last Earnings Report: Can It Continue?Nasdaq
- Leerink Partners Upgrades Abbott Laboratories to Outperform from Market PerformNasdaqABT, HEI.A
- 3 Dividend Kings to Buy in November and Never SellNasdaqABT, MCD, TNC
- Abbott Begins Clinical Trial Of Software-Guided TAVI System For Aortic StenosisNasdaq
- Notable ETF Outflow Detected - XLV, ABT, PFE, ISRGNasdaqXLV, ABT, PFE, ISRG
- Abbott Laboratories Extends Change in Control Agreements to December 31, 2028Nasdaq
- Here's How Abbott's EP Business Is Shaping Up for the Rest of 2026NasdaqABT, TMO, PODD
- Pfizer's 5.9% Yield vs. AbbVie's 53-Year Dividend Streak: Which Stock Is the Better Buy?NasdaqABBV, PFE, ABT
Abbott Laboratories peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NVONovo Nordisk A/S | 37.82 | -2.70% | $166.69B | vs ABT |
| PFEPfizer Inc. | 27.40 | -0.51% | $156.18B | vs ABT |
| VRTXVertex Pharmaceuticals Incorporated | 515.02 | -1.08% | $130.58B | vs ABT |
| BMYBristol-Myers Squibb Company | 58.80 | +0.79% | $120.19B | vs ABT |
| SNYSanofi ADS | 46.52 | +1.00% | $111.70B | vs ABT |
| GSKGSK plc ADR | 47.76 | -0.13% | $95.73B | vs ABT |
| REGNRegeneron Pharmaceuticals Inc. | 920.69 | -0.19% | $95.24B | vs ABT |
| AZNAstraZeneca PLC | 174.35 | -0.60% | $270.40B | vs ABT |
Indexes, lists and sector
Abbott Laboratories stock FAQ
What is Abbott Laboratories's stock price today?
ABT last traded at $103.00 as of Nov 20, 4:02 PM EST, down 0.84% on the day. Prices are delayed at least 15 minutes.
Does Abbott Laboratories pay a dividend?
Yes. Abbott Laboratories pays $2.52 per share annually, a 2.45% yield. The most recent dividend of $0.63 had an ex-dividend date of Oct 15, 2026.
What is ABT's P/E ratio?
ABT trades at a trailing P/E ratio of 38.43 and a forward P/E of 17.35, compared with a median of 21.7 for its closest peers.
Is Abbott Laboratories in the S&P 500?
Yes. Abbott Laboratories (ABT) is a constituent of the S&P 500 index.
Who is Abbott Laboratories's CEO?
Mr. Robert B. Ford is the chief executive officer of Abbott Laboratories, which has about 122,000 employees.
Has ABT ever split its stock?
Yes. The most recent ABT stock split was a 10000-for-4798 split on Jan 2, 2013, one of 7 splits on record.
What is the ABT 52-week high?
The 52-week high for ABT is $129.85 and the 52-week low is $81.97. The stock is currently 20.7% below its high.